Trial reportJournal of pediatric gastroenterology and nutrition2026
The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.
Trial report in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.Journal of pediatric gastroenterology and nutrition · 2026Trial
- Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesVonoprazan, a potassium-competitive acid blocker, provides more rapid, potent, and durable elevations in gastric pH than proton pump inhibitors in adults and may be a treatment option for adolescents and children with gastroesophageal reflux disease (GERD). The pharmacokinetics and safety of vonoprazan in pediatric subjects (6-17 years) with symptomatic GERD were evaluated in two clinical studies.
methodsForty-two subjects were randomized to vonoprazan 10 or 20 mg once daily for 14 days. Plasma vonoprazan concentrations were analyzed employing a two-compartment population pharmacokinetic model developed using adult data. Individual estimates of maximum concentration at steady state (C
resultsModel-based analyses showed that exposures (AUC
conclusionsExposures of vonoprazan in adolescents and children were nearly identical to exposures observed in adults, confirming the appropriateness of vonoprazan 10 and 20 mg doses in a pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.